IL17A and Eczematoid dermatitis: Although the underlying pathophysiology of this entity remains ill-defined, a previous study evaluating biopsies from psoriasis and eczema found that the upregulation of both IL-36 and beta-defensin 2 can induce IL-17 pathway activation and is seen preferentially in psoriatic lesions as compared with eczema.2